REACH24, the 7th International LFS Association Symposium, is the largest Li-Fraumeni syndrome(LFS) conference in the world and will include over 400 attendees from all over the globe. This hybrid event, combining in-person and virtual participation, is hosted by Penn Medicine and Children's Hospital of Philadelphia in partnership with the LiFE Consortium.
The conference will take place from October 18-22, 2024. The LFS Association will welcome attendees on the afternoon of October 18th, beginning with registration in the afternoon followed by a welcome reception in the evening. Sessions will commence on the morning of October 19th.
Event highlights will include in-person and virtual sessions with Q&A panels, social engagement for both on-site and virtual attendees, engaging poster sessions, and more. The symposium will cover a wide range of crucial scientific and clinical research topics, such as genetics, global perspectives on LFS, emerging therapies, and special sessions focusing on the mental health of individuals living with LFS and their families.
This symposium uniquely enables families to engage directly with leading LFS physicians, scientists, and genetic counselors, creating an opportunity for them to learn from one another, gaining critical knowledge and insight.
REACH24 aims to unite, support, and advocate for those affected by LFS while sharing the latest advancements and fostering connections among attendees.
Meet the Speakers
Judy E. Garber, MD, MPH, is the Susan F. Smith Chair and Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School, LFSA Medical Advisory Board (member). She conducts research in clinical cancer genetics, with a special focus in genetics of breast cancer and is an expert on Li-Fraumeni Syndrome.
Christian Kratz, MD, is the Chair and Professor of Pediatric Hematology and Oncology at Hannover Medical School, LFSA Medical Advisory Board (member) and LFSA – Germany (chapter founder), has been a leader in cancer predisposition research and leads the Li-Fraumeni syndrome (LFS) registry, launched in 2017 and has enrolled over 300 patients of different age groups with LFS.
Arnold Levine, PhD, Professor Emeritus at the Institute for Advanced Study, Princeton, N.J., LFSA Scientific Advisory Board (co-chair) worked with others to discover the p53 tumor suppressor protein in 1979. The Levine research group has since provided clear evidence that the p53 pathway plays a central role in the prevention of human cancers, the influence of and that polymorphic variations in components of the pathway, and helped to uncover the genetic origins of cancer and focus drug discovery on a rational path to treat cancers.
David Malkin, MD , is a pediatric oncologist and clinician-scientist at the Hospital for Sick Children (SickKids) in Toronto where he holds the CIBC Children's Foundation Chair in Child Health Research, LFSA Medical Advisory Board (member) and LFSA – Canada (chapter co-chair). He co-Directs the SickKids Cancer Genetics Program and co-leads the SickKids Cancer Sequencing (KiCS) program. Dr. Malkin's primary research focuses on strategies to translate fundamental discoveries of TP53's role in human cancer to innovative early detection and cancer interception strategies in families with LFS.